What is Grifols, S.A. (GIFLF)?

Grifols, S.A. (GIFLF) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of GIFLF?

The current price of GIFLF is $10.55. Prices are updated in real time on Stocks360.

What is GIFLF's price-to-earnings (PE) ratio?

GIFLF's trailing twelve-month PE ratio is 16.38, based on current price and earnings per share data available on Stocks360.

What is GIFLF's market capitalization?

GIFLF's market capitalization is $7,180,123,959.00, placing it in the mid-cap tier.

Does GIFLF pay a dividend?

Yes. GIFLF has a trailing twelve-month dividend yield of 0.01%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Grifols, S.A. (GIFLF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - General

$10.55

Market Cap

$7.18B

PE (TTM)

16.38

EPS (TTM)

N/A

Dividend Yield

0.75%

Beta

1.19

Day Range

$10.55 – $11.69

52-wk Range

$10.13 – $13.90

Avg Volume

N/A

Volume

50.00

Grifols, S.A. (GIFLF) is a publicly traded company in the Healthcare sector. Latest price: $10.55. Market cap $7.18B. Trailing PE 16.38. Dividend yield 0.75%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $13.90 2026-10-30 · $10.55 (-24.10%)

Earnings

Most Recent

Jul 28, 2026

EPS $0.25 vs est. $0.26

Missed by $0.01

Next Earnings

Nov 2, 2026

EPS estimate $0.32

Proprietary Signals

Signal snapshot temporarily unavailable.

About Grifols, S.A.

Grifols, S.A., a company established in Barcelona, Spain, in 1940, specializes in the sourcing, production, and sale of therapeutic products, principally derived from blood plasma. Its diverse activities are structured across five main divisions. The Bioscience division spearheads the research, development, manufacturing, and commercialization of plasma-derived medications and novel solutions designed to treat chronic, rare, widespread, and life-threatening diseases. Its portfolio includes immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. Through its Hospital division, Grifols supplies non-biological pharmaceutical products and medical provisions, encompassing clinical nutrition, intravenous therapies, and various medical devices. The Diagnostic division focuses on developing and distributing diagnostic tools that support healthcare professionals throughout the patient journey, from prevention and screening to accurate diagnosis, prognosis, and continuous treatment monitoring. Additionally, the Bio Supplies division furnishes crucial biological materials for scientific research, clinical trials, and the production of pharmaceutical and dia…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	16.38×
P/S (TTM)	0.89×
P/B	1.35×
PEG	0.29×
P/FCF (TTM)	8.58×
EV / EBITDA	8.34×
EV / Sales	1.97×
Earnings Yield	6.05%
Free Cash Flow Yield	11.65%
Dividend Yield	0.75%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$14.59B
Revenue (TTM)	$7.42B
Net Income (TTM)	$398.37M
Free Cash Flow (TTM)	$1.11B
Net Debt	$8.00B
Working Capital	$3.07B
Gross Margin	37.23%
Operating Margin	16.66%
Net Margin	6.09%
Return on Equity	8.43%
Return on Invested Capital	5.47%